PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1314-1322

  Galiè, Nazzareno ^a   Müller, Katharina ^b   Scalise, Andrea Viviana ^c   Grünig, Ekkehard ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BAYER PHARMA AG   (Germany)

^c Bayer Hispania   (Spain)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIOCIGUAT; SILDENAFIL; ANTIHYPERTENSIVE AGENT; GUANYLATE CYCLASE; PHOSPHODIESTERASE V INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; ATRIAL FIBRILLATION; CLINICAL ARTICLE; COLITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERYSIPELAS; EXERCISE; FAINTNESS; FEMALE; FEVER; HEADACHE; HEART ARREST; HEART INDEX; HEART RATE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOKALEMIA; HYPOTENSION; HYPOXIA; INTERSTITIAL LUNG DISEASE; INTERVERTEBRAL DISK HERNIA; JOINT DISLOCATION; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAINTENANCE DRUG DOSE; MALE; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SUBDURAL HEMATOMA; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL; UNCONSCIOUSNESS; VOMITING; CHEMISTRY; CLINICAL TRIAL; DIASTOLE; DRUG EFFECTS; EUROPE; FOLLOW UP; HEMODYNAMICS; HYPERTENSION, PULMONARY; MIDDLE AGED; PATIENT SAFETY; SYSTOLE;

AGED; ANTIHYPERTENSIVE AGENTS; DIASTOLE; DOUBLE-BLIND METHOD; EUROPE; EXERCISE; FEMALE; FOLLOW-UP STUDIES; GUANYLATE CYCLASE; HEART RATE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PATIENT SAFETY; PHOSPHODIESTERASE 5 INHIBITORS; PYRAZOLES; PYRIMIDINES; SILDENAFIL CITRATE; SYSTOLE;

EID: 84928998319     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00105914     Document Type: Article

References (19)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
2. Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: D60-D72.
3. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
4. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448-456.
5. Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 188: 639-646.
6. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2010; 123: 2263-2273.
7. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013; 218: 279-313.
8. Follmann M, Griebenow N, Hahn MG, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl 2013; 52: 9442-9462.
9. Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 2011; 20: 567-576.
10. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009; 277-308.
11. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-340.
12. Conole D, Scott LJ. Riociguat: first global approval. Drugs 2013; 73: 1967-1975.
13. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-329.
14. Pfizer. Revatio®: US prescribing information. www.accessdata.fda.gov/drugsatfda-docs/label/2014/021845s011, 022473s004, 0203109s002lbl.pdf Date last updated: 2014.
15. Bayer HealthCare Pharmaceuticals. Adempas®. EU summary of product characteristics. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002737/WC500165034.pdf Date last updated: 2014.
16. Bayer HealthCare Pharmaceuticals. Adempas® US prescribing information. http://labeling.bayerhealthcare.com/html/products/pi/Adempas-PI.pdf Date last updated: 2013.
17. Pfizer. Revatio®: EU summary of product characteristics. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000638/WC500055840.pdf Date last updated: 2014.
18. Rubin LJ, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: A long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1303-1313.
19. Rubin LJ, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A phase III long-term extension study (PATENT-2). Am J Respir Crit Care Med 2013; 187: A3531.